EGFR L861Q mutation is a frequent feature of pulmonary mucoepidermoid carcinoma.

Shanghai Lung Cancer Center, Chest Hospital Affiliated to Shanghai Jiaotong University, 241 West Huaihai Road, Xuhui District, Shanghai 200030, China.
Journal of Cancer Research and Clinical Oncology (Impact Factor: 3.01). 04/2012; 138(8):1421-5. DOI: 10.1007/s00432-012-1211-5
Source: PubMed

ABSTRACT The purpose of this study is to assess the feasibility of targeted treatment for pulmonary mucoepidermoid carcinoma (PMEC) by investigating track record of the epidermal growth factor receptor (EGFR) mutation status in PMEC.
From January 2001 to December 2009, 20 PMEC patients (11 males and 9 females) received treatment in our center. All the patients received surgery and were diagnosed by pathology. Sequencing analysis was used to monitor exons 18-21 of the EGFR gene mutation.
The exon 21 L861Q heterozygous mutation was confirmed in five patients. There was no case with any deletion in exon 19 or exon 21 L858R mutation. One case was with a homonymy exon 18 mutation (I760I). Exon 20 G2607A (Q787Q) SNP was found in 12 of those 20 patients.
L861Q mutation in exon 21 is the most frequent feature of heterozygous mutation in our study. Further investigations will be required to validate our findings.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mucoepidermoid tumours (TME) are rare tumours arising from the submucosal glands of the tracheobronchial tree. The majority of these tumours develop in a benign fashion but some of them are malignant. The latter can be easily mistaken for adenosquamous carcinomas. We have reviewed 22 patients suffering from TME observed over a period of 25 years. Two arose from the trachea and 20 from the cartilaginous bronchi; 12 of these tumours had macroscopic and histological criteria of low-grade malignancy, 4 had macroscopic and 6 macroscopic and microscopic criteria of high grade malignancy. Prognosis of the latter was very poor and no survival observed after 6 years follow-up, a behavior similar to that observed in non-small cell lung carcinomas and adenosquamous carcinomas. The best treatment of these orphan tumours remains surgery. Copyright © 2014 Elsevier Masson SAS. All rights reserved.
    Revue de Pneumologie Clinique 02/2015; DOI:10.1016/j.pneumo.2014.09.007 · 0.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 59-year-old man was admitted to our hospital with dyspnea and cough. A large polypoid tumor was observed in the lower trachea and bronchoscopic polypectomy was performed using a snare to relieve symptoms. The tumor was diagnosed as a high grade mucoepidermoid carcinoma mainly by the histology of piecemeal specimens obtained by bronchoscopic resection. The primary lesion involved the trachea and the main bronchus, and there were multiple metastases in the lung. The patient was treated with the combination of carboplatin and paclitaxel. After four cycles of chemotherapy, the tumors were significantly reduced. He remains well without evidence of tumor progression for 25 months. This case suggests that the combination chemotherapy of carboplatin and paclitaxel can be an option for treatment of pulmonary mucoepidermoid carcinoma.
    Japanese Journal of Clinical Oncology 03/2014; 44(5). DOI:10.1093/jjco/hyu016 · 1.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lung cancers presenting two different histologic types are relatively rare. This paper presents a case report of mixed lung cancer comprising mucoepidermoid carcinoma and conventional adenocarcinoma, a combination that has not been reported previously. These two carcinomas showed distinct morphologic and immunohistochemical features. However, gene analysis revealed identical mutations in each component, which indicates they possess a monoclonal origin. Specifically, we identified the same mutation in exon 19 of the epidermal growth factor receptor gene. Molecular analysis further substantiated a monoclonal origin with divergent differentiation, as opposed to the collision of discrete tumors.
    The Annals of Thoracic Surgery 08/2014; 98(2):695-7. DOI:10.1016/j.athoracsur.2013.10.035 · 3.63 Impact Factor